Preparation of an alternative freeze-dried pH-sensitive cyclosporine A loaded nanoparticles formulation and its pharmacokinetic profile in rats

Pharmazie

Volumn 64, Issue 1, 2009, Pages 26-31

  Yang, Zhi Qiang ^a   Xu, Jie ^a   Pan, Ping ^a   Zhang, Xue Nong ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPROTECTIVE AGENT; CYCLOSPORIN A; LACTOSE; NANOPARTICLE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; EMULSION; ENCAPSULATION; FREEZE THAWING; MALE; NONHUMAN; PARTICLE SIZE; PH MEASUREMENT; RAT; ANIMAL; AREA UNDER THE CURVE; BIOAVAILABILITY; CHEMISTRY; FREEZE DRYING; PH; SPRAGUE DAWLEY RAT; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CRYOPROTECTIVE AGENTS; CYCLOSPORINE; DRUG COMPOUNDING; FREEZE DRYING; HYDROGEN-ION CONCENTRATION; IMMUNOSUPPRESSIVE AGENTS; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 62649124315     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2008.8029     Document Type: Article

References (31)

1. Auvillain M, Cavé G, Fessi H, Devissaguet JP (1989) Lyophilisation de vecteurs collodaux submicroniques. STP Pharma 5: 738-744.
2. Bhardwaj V, Hariharan S, Bala I, Lamprecht A, Kumar N, Panchagnula R, Kumar MNVR (2005) Pharmaceutical aspects of polymeric nanoparticles for oral drug delivery. J Biomed Nanotech 1: 235-258.
3. Cavanak T, Sucker H (1986) Formulation of dosage forms. Progr Allergy 38: 65-72.
4. Hariharan S, Bhardwaj V, Bala I, Sitterberg J, Bakowsky U, Kumar MNVR (2006) Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharm Res 23: 184-195.
5. Chacón M, Berges L, Molpeceres J (1996) Optimized preparation of poly d,l(lactic-glycolic) microspheres and nanoparticles for oral administration. Int J Pharm 141: 81-91.
6. Crowe LM, Reid DS, Crowe JH (1996) Is trehalose special for preserving dry biomaterials? Biophys J 71: 2087-2093.
7. De Jaeghere F, Allemann E, Leroux JC, Stevels W, Feijen J, Doelker E, Gumy R (1999) Formulation and lyoprotection of poly(lactic acid-co-ethylene oxide) nanoparticles: Influence on physical stability and in vitro cell uptake. Pharm Res 16: 859-866.
8. De Chasteigner S, Cave G, Fessi H, Devissaguet JP, Puisieux F (1996) Freeze-drying of itraconazole-loaded nanosphere suspensions: a feasibility study. Drug Dev Res 38: 116-124.
9. Drewe J, Beglinger C, Kissel T (1992) The absorption site of cyclosporine in the human gastrointestinal tract. Br J Clin Pharm 33: 39-43.
10. El-Shabouri MH (2002) Positively charged nanoparticles for improving the oral bioavailability of cyclosporine-A. Int J Pharm 249: 101-108.
11. Guterres SS, Fessi H, Barrat G, Devissaguet JR, Puisieux F (1995) Poly(d,l-lactide) nanoparticles containing diclofenac: I Formulation and stability study. Int J Pharm 113: 57-63.
12. Hancock BC, Zoografi G (1997) Characteristics and significance of the amorphous state in pharmaceutical system. J Pharm Sci 86: 1-11.
13. Italia JL, Bhatt DK, Bhardwaj V (2007) PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J Control Release 119: 197-206.
14. Kahan BD, Podbielski J, Napoli KL, Katz SM (1998) Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 66: 1040-1046.
15. Kovarik JM, Mueller EA, Van Bree JB, Tetzloff W, Kutz K (1994) Reduced inter- and intra-individual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 83: 444-446.
16. Kawashima Y, Niwa T, Handa T, Takeuchi H, lwamoto T, Itoh K (1989) Preparation of controlled-release microspheres of ibuprofen with acrylic polymers by a novel quasi-emulsion solvent diffusion method. J Pharm Sci 78: 68-72.
17. Luke DR, Kasiske BL, Matzke GR, Awni WM, Keane WF (1987) Effect of cyclosporine on the isolated perfused rat kidney. Transplantation 43: 795-799.
18. Lee Eun-Jin, Lee Sa-Won, Choi Han-Gon, Kim Chong-Kook (2001) Bio-availability of cyclosporine A dispersed in sodium lauryl sulfate-dextrin based solid microspheres. Int J Pharm 218: 125-131.
19. Matzke GR, Luke DR (1988) Dialysis and renal transplant therapy. In: Herfindal ET, Gourley, DR, Hart LL (eds.) Clinical Pharmacy and Therapeutics. Williams & Wilkins, Baltimore, pp. 229-242.
20. Mithani SD, Bakatselou V, Tenhoor CN, Dressman JB (1996) Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm Res 13: 163-167.
21. Molpeceres J, Aberturas MR, Chacon M, Berges L, Guzman M (1997) Stability of cyclosporine-loaded poly-e-caprolactone nanoparticles. J Microencapsulation 14: 777-787.
22. Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MNV (2007) Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release 119: 77-85.
23. McClean S, Prosser E, Mechan E, O'Malley D, Clarke N, Ramtoola Z, Brayden D (1998) Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia. Eur J Pharm Sci 6: 153-163.
24. Ozaki K, Hayashi M (1997) The effects of glucose oligomers (maltodextrins) on freeze-drying liposomes. Chem Pharm Bull 45: 165-170.
25. Sun WQ, Leopold AC, Crowe LM, Crowe JH (1996) Stability of dry liposomes in sugar glasses. Biophys J 70: 1769-1776.
26. Saez A, Guzmán M, Molpeceres J, Aberturas MR (2000) Freeze-drying of polycaprolactone and poly(D,L-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs. Eur J Pharm Biopharm 50: 379-387.
27. Thomson, N (1991) Cyclosporin: use outside transplantation. Brit Med J 302: 4-5.
28. Taylor NE, Mark AE, Vallat P, Brunne RM, Testa B, Van Gunteren WF (1993) Solvent dependent conformation and hydrogen bounding capacity of cyclosporine A: evidence from partition coefficient and molecular dynamics simulations. J Med Chem 36: 3753-3764.
29. Tjai JF, Webber IR, Back DJ (1991) Cyclosporin metabolism by the gastrointestinal mucosa. Br J Clin Pharmacol 31: 344-346.
30. Varela MC, Guzmán, M, Molpeceres J (2001) Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats. Eur J Pharm Sci 12: 471-478.
31. Wang XQ, Dai JD, Zhang Q (2004) Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration. J Control Release 97: 421-429.